Second- or third-generation tyrosine kinase inhibitors in first-line treatment of chronic myeloid leukemia in general population: Is there a real benefit?

Date publication

septembre 2021

Journal

Cancer medicine

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MAYNADIE Marc

Tous les auteurs :
Canet J, Cony-Makhoul P, Orazio S, Cornet E, Troussard X, Maynadié M, Étienne G, Monnereau A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34551198

Résumé

Since 2009, multiple randomized trials have shown faster and deeper responses in CML patients treated with new-generation TKI (NG-TKI) compared to those treated with imatinib (IM). Are the same results observed in the general population?

Mots clés

chronic myeloid leukemia, observational study, population-based cancer registries, real life, tyrosine kinase inhibitor

Référence

Cancer Med. 2021 Sep 22;: